Literature DB >> 18441341

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Vincent Soriano1, Alan S Perelson, Fabien Zoulim.   

Abstract

The arrival of new antiviral drugs to treat chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections has given rise to great expectations along with concerns regarding the selection of drug-resistant variants. Many lessons learnt from HIV therapeutics can be helpful for designing adequate treatment strategies against viral hepatitis, the avoidance of sequential weak monotherapies being one of them. Although HIV, HBV and HCV share many biological features, including very rapid viral dynamics, distinctive characteristics explain why the speed of selection of drug resistance differs substantially between these viruses, being faster for HCV than for HIV and slower for HBV.

Entities:  

Mesh：

Year:  2008        PMID： 18441341      PMCID： PMC2574594          DOI： 10.1093/jac/dkn175

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  31 in total

Review 1.  Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.

Authors:  Vincent Soriano; Massimo Puoti; Maurizio Bonacini; Gary Brook; Antonietta Cargnel; Juergen Rockstroh; Chloe Thio; Yves Benhamou
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

2.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

Review 3.  Dynamics of HIV-1 and CD4+ lymphocytes in vivo.

Authors:  A S Perelson; P Essunger; D D Ho
Journal:  AIDS       Date:  1997       Impact factor: 4.177

4.  Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus.

Authors:  G Moraleda; J Saputelli; C E Aldrich; D Averett; L Condreay; W S Mason
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.

Authors:  M Tsiang; J F Rooney; J J Toole; C S Gibbs
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

6.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

7.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Authors:  Bettina Werle-Lapostolle; Scott Bowden; Stephen Locarnini; Karsten Wursthorn; Jorg Petersen; George Lau; Christian Trepo; Patrick Marcellin; Zachary Goodman; William E Delaney; Shelly Xiong; Carol L Brosgart; Shan-Shan Chen; Craig S Gibbs; Fabien Zoulim
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

8.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

9.  Viral dynamics in hepatitis B virus infection.

Authors:  M A Nowak; S Bonhoeffer; A M Hill; R Boehme; H C Thomas; H McDade
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Authors:  Vincent Soriano; Ivana Maida; Marina Núñez; Javier García-Samaniego; Pablo Barreiro; Luz Martín-Carbonero; Juan González-Lahoz
Journal:  Antivir Ther       Date:  2004-12
View more
  23 in total

1.  Hepatitis: Treatment failure in chronic hepatitis B.

Authors:  Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-04       Impact factor: 46.802

2.  Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors:  Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

3.  Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.

Authors:  Thierry Verbinnen; Herwig Van Marck; Ina Vandenbroucke; Leen Vijgen; Marijke Claes; Tse-I Lin; Kenneth Simmen; Johan Neyts; Gregory Fanning; Oliver Lenz
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

4.  Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.

Authors:  C K S Chui; W W Y Dong; J B Joy; A F Y Poon; W Y Dong; T Mo; C K Woods; C Beatty; H Hew; P R Harrigan; C J Brumme
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

5.  Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.

Authors:  Libin Rong; Ruy M Ribeiro; Alan S Perelson
Journal:  Bull Math Biol       Date:  2012-05-26       Impact factor: 1.758

6.  A novel small molecule inhibitor of hepatitis C virus entry.

Authors:  Carl J Baldick; Michael J Wichroski; Annapurna Pendri; Ann W Walsh; Jie Fang; Charles E Mazzucco; Kevin A Pokornowski; Ronald E Rose; Betsy J Eggers; Mayla Hsu; Weixu Zhai; Guangzhi Zhai; Samuel W Gerritz; Michael A Poss; Nicholas A Meanwell; Mark I Cockett; Daniel J Tenney
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

7.  Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.

Authors:  Jie Fang; Michael J Wichroski; Steven M Levine; Carl J Baldick; Charles E Mazzucco; Ann W Walsh; Bernadette K Kienzle; Ronald E Rose; Kevin A Pokornowski; Richard J Colonno; Daniel J Tenney
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

8.  Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.

Authors:  Severine Margeridon-Thermet; Evguenia S Svarovskaia; Farbod Babrzadeh; Ross Martin; Tommy F Liu; Mary Pacold; Elizabeth C Reuman; Susan P Holmes; Katyna Borroto-Esoda; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

9.  Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.

Authors:  Minhee Kang; Kimberly Hollabaugh; Vinh Pham; Susan L Koletar; Kunling Wu; Marlene Smurzynski; Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

10.  Identification of HCV protease inhibitor resistance mutations by selection pressure-based method.

Authors:  Ping Qiu; Vincent Sanfiorenzo; Stephanie Curry; Zhuyan Guo; Shaotang Liu; Angela Skelton; Ellen Xia; Constance Cullen; Robert Ralston; Jonathan Greene; Xiao Tong
Journal:  Nucleic Acids Res       Date:  2009-04-24       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.